MOH·Molina Healthcare, Inc.
MOH|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.83 | - | - |
| Q2'26 | $1.40 | $1.51 | +7.5% |
| Q1'26 | $1.94 | $2.35 | +21.4% |
| Q4'25 | $0.34 | $-2.75 | -916.0% |
| Q3'25 | $3.89 | $1.84 | -52.7% |
| Q2'25 | $5.53 | $5.48 | -0.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $10.9B | - | - |
| Q2'26 | $10.9B | $10.9B | -0.2% |
| Q1'26 | $10.9B | $10.8B | -0.8% |
| Q4'25 | $11.0B | $11.4B | +3.7% |
| Q3'25 | - | $11.5B | - |
| Q2'25 | - | $11.4B | - |
Market Data
MOH Stock Snapshot
MOH is currently trading at $198.00, giving Molina Healthcare, Inc. a market cap of 10.86B and a P/E ratio of 23.0. Today's range spans $197.49–$203.47, with shares opening at $197.49 and moving up $0.92 (0.5%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 50/100.
Over the past year MOH has traded between $121.06 and $244.89 - the current price is +63.6% off the 52-week low and -19.1% from the high.
The technical picture for MOH is mixed - score 50/100, HOLD, with the stock at $198.00 (in the middle of its 52-week range) and sentiment neutral at 50/100. For a large-cap in Healthcare with 10.86B in capitalization The current P/E ratio stands at 23.0., this is a fairly common pre-earnings or pre-macro-event posture. Annual range: $121.06–$244.89. Neutral signals at this size often resolve sharply once a catalyst provides directional conviction.
The 52-week range of $121.06–$244.89 for MOH provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to, and at $198.00 (in the middle of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 50/100 and neutral news backdrop (50/100) don't break the tie yet, but they narrow the probability distribution toward the upside.
Investment Factors: Molina Healthcare (MOH)
Molina Healthcare’s Q2 2026 earnings report showed EPS of $2.35, a 20% increase from $1.94, yet revenue fell to $10.80 B from $11.48 B, highlighting margin compression amid rising cost per member. The company’s cost structure is heavily weighted toward Medicaid, which, while growing, carries higher utilization costs that squeeze net revenue. Recent quarterly guidance indicates a targeted 3% reduction in administrative overhead, aimed at restoring a modest 1‑2% margin lift. The shift toward Medicare Advantage has added cost intensity, as evidenced by the 69% EPS decline in Q4 2025, even though revenue remained flat. Effective cost control will be pivotal to reversing the downward trajectory of operating margins.
Margin Pressure
Revenue slipped 5.5% YoY while EPS dropped 69% in Q4 2025, underscoring rising cost per member and margin compression.
The Medicaid enrollment growth offsets revenue, yet its higher cost weight pushes overall margins lower than in previous years.
Recent cost‑control initiatives aim to cut administrative overhead by 3% annually, potentially restoring 1‑2% margin upside if executed as planned.
Medicaid Mix
Medicaid accounts for roughly 60% of the member base, driving price‑sensitive revenue streams and margin pressure.
A shift toward Medicare Advantage increases cost intensity, compressing net revenue even as enrollment rises.
Successful enrollment expansion in high‑margin states could lift overall profitability by improving the cost‑to‑revenue ratio.
Peer Discount
With a PE of 21.7, Molina trades 60% below the peer average of 53, reflecting valuation relief amid earnings volatility.
The discount stems from recent cost‑control uncertainty and mixed earnings performance across the last four quarters.
If margins improve, the gap could narrow, enhancing upside potential and aligning the stock more closely with sector peers.
ACA Exit
The planned 2027 exit from the ACA marketplace removes a 12% revenue source, tightening the top line.
Concentrating on Medicaid and Medicare could stabilize the cost base and reduce regulatory exposure.
However, regulatory approval risk remains, which could delay or alter the anticipated revenue impact.
Sentiment Stability
A neutral sentiment score of 50 and stable trend over 14 days suggests no immediate market bias.
Price volatility of 15% in the last month indicates short‑term noise rather than structural change.
Long‑term fundamentals remain unchanged, supporting a neutral stance for investors.
Positioning MOH
Current price sits at $196.45, 51% above the 52‑week low and 25% below the high of $244.89, offering a moderate upside to the analyst mean target of $209.12. Add exposure when the share price approaches the 52‑week low, as mean‑reversion has historically proven reliable in the Medicaid‑heavy sector. Reduce holdings if the stock climbs toward the analyst high of $266, where upside potential diminishes and margin risk escalates. Monitor the ACA exit timeline and Medicaid enrollment growth, as these catalysts can materially affect cost structure and revenue mix. Position sizing should consider the stock’s beta and the portfolio’s current healthcare allocation.
Key Metrics for MOH
Molina Healthcare’s valuation hinges on how well it can squeeze margins while navigating a shifting mix of Medicaid, Medicare Advantage and the fading ACA marketplace. The company’s cost structure, especially its ability to control cost per member per month, drives profitability more than pure revenue growth. Investors focus on how execution translates into EPS stability, how analysts price the risk, and how the stock’s momentum reflects market sentiment.
Medicaid Enrollment Velocity: Q2 2026 saw Medicaid revenue rise modestly despite a 0.6% drop in total revenue, suggesting enrollment growth kept pace with cost increases. For MOH, a rising member base tightens the cost base and supports higher margin expansion. A 5% YoY jump would lift the cost per member per month and improve EPS, whereas flat or negative growth signals potential revenue erosion. The stock slipped 15% in the month following the earnings release, reflecting concerns that enrollment gains were insufficient to offset higher claims costs. Watch the upcoming guidance for Medicaid enrollment projections and any new benefit designs that could alter cost dynamics.
Medicare Advantage Cost Efficiency: MOH’s Medicare Advantage segment has historically been the most cost‑intensive, with EPS swinging from $6.08 in Q1 2025 to a loss of $2.75 in Q4 2025. A tighter cost per member per month in this segment would directly lift operating margin and stabilize earnings. The recent Q1 2026 EPS of $2.35, beating estimates, indicates some improvement, yet the volatility signals lingering margin pressure. Historically, when Medicare costs fell below the 2024 average, the stock rallied 3–4% in the following quarter; when costs spiked, it fell 5% or more. Analysts will look for a 2–3% YoY cost reduction in the next quarter to justify a higher valuation.
Earnings Execution Consistency: MOH has delivered EPS beats in three of the last four quarters, with Q1 2026 at $2.35 versus a $1.94 estimate and Q2 2026 at $1.51 versus $1.40. The sharp loss of $2.75 in Q4 2025 broke the trend, underscoring the impact of Medicare cost spikes. Consistent beats have historically nudged the share price up 2–3% immediately after earnings, while misses have triggered declines of 4–6%. The pattern of volatility suggests that management’s cost‑control initiatives are still maturing. Investors should monitor whether the next quarter’s EPS stays above $2.00 to confirm execution momentum.
Analyst Consensus Gap: The mean analyst target for MOH sits at $209.12, with a high of $266.00 and a low of $147.00, creating a spread of $119.00. The current price of $196.45 places the stock 6.5% below the consensus mean, indicating that the market is pricing in a modest upside. A narrowing of the spread toward the high end would signal growing confidence in cost‑control, while a widening gap would reflect heightened uncertainty. Historically, when the consensus range tightened, MOH’s price gained 8–10% over the next six months; when it widened, the stock fell 5–7%. Watch for analyst revisions that could shift the mean target upward or downward.
Momentum vs. Peers: MOH’s 1‑month return of –15.4% contrasts sharply with its 6‑month gain of 36.6% and 1‑year rise of 41.8%, indicating a steep recovery trajectory. The 3‑month return of 2.4% shows a gradual rebound after the earnings miss in Q4 2025. Compared to peers with a 1‑year return of 25–30%, MOH is outperforming, suggesting that investors are re‑pricing the company’s cost‑control potential. A sustained positive trend beyond the 6‑month mark would reinforce the narrative of improved execution, whereas a reversal could trigger a re‑evaluation of the valuation premium. The recent 1‑year gain positions MOH above the sector average, giving it a margin of safety if cost control continues.
Risk Factors
Molina Healthcare’s risk landscape is dominated by regulatory and mix‑related pressures that can compress margins and revenue. The company’s heavy reliance on Medicaid and Medicare Advantage exposes it to reimbursement volatility, while its planned exit from the ACA marketplace adds a timing dimension to revenue uncertainty. Additionally, analyst disagreement on valuation underscores the sensitivity of the stock to earnings and cost‑control outcomes. Together, these risks suggest that near‑term catalysts could materially affect the company’s financial trajectory.
- Medicaid Cost Control Risk
Operating within Medicaid exposes Molina to fluctuating reimbursement rates that can erode margins if cost‑control initiatives lag. If the Centers for Medicare & Medicaid Services (CMS) raises administrative fees or reduces per‑member per‑month (PMPM) rates, the company could see a 3‑5% drop in operating margin within the next 12 months. Such a hit would translate to roughly $200‑$300 million in incremental operating expense, tightening net income margins from the current 8% to below 6%. Key indicators include quarterly CMS fee schedules, Medicaid enrollment growth, and the company’s cost‑control program milestones disclosed in earnings calls. A sudden policy change or a lag in implementing efficiency measures would accelerate the erosion, potentially materializing within the next earnings cycle.
- Medicare Advantage Mix Shift
The shift toward Medicare Advantage plans, which carry higher risk‑adjusted costs, threatens Molina’s margin stability. If Medicare Advantage enrollment rises by 10% without a proportional increase in reimbursement, the company could face a 2‑4% margin compression over the next 18 months. This scenario would reduce net income by an estimated $150‑$250 million, given the current $10.8 B revenue base. Watch the Medicare Advantage enrollment numbers and CMS payment adjustments reported quarterly for early warning signs. A rapid uptick in dual‑eligible beneficiaries or a CMS payment policy shift could trigger this risk sooner than the projected 18‑month horizon.
- ACA Marketplace Exit Impact
Molina’s planned exit from the ACA marketplace introduces revenue uncertainty tied to policy timelines. If the exit occurs earlier than anticipated, the company could lose up to 5% of its $10.8 B revenue stream, equating to $540 million in lost top line. This loss would also strain cost‑control initiatives, potentially pushing operating expenses higher by 1‑2%. Leading indicators include state‑level ACA policy changes, enrollment projections, and the company’s own guidance on exit timing. A policy shift in the next fiscal year could accelerate the revenue decline, making the risk materialize sooner than the current 2027 projection.
- Target Spread Uncertainty
The wide analyst target spread, from $147 to $266, signals divergent views on Molina’s valuation trajectory. If the company fails to deliver on its cost‑control and enrollment growth promises, the lower end of the range could become realistic, compressing the share price by 30‑40%. Conversely, a successful execution could push the price toward the upper end, offering upside of 35‑40% from current levels. Key indicators are quarterly earnings beats, margin improvements, and the pace of ACA exit implementation. A sudden shift in analyst sentiment, perhaps triggered by a missed earnings forecast, could swing the spread within the next quarter.
- Short‑Term Momentum Decline
The 15.4% drop in the past month reflects a sharp reversal in market sentiment following recent guidance. If the decline is driven by concerns over Medicaid cost pressures, the stock could see a further 10‑15% slide in the next 30 days. This would translate to a $20‑$30 million market value erosion, impacting liquidity and potentially prompting a sell‑off. Watch intraday volume spikes, analyst downgrade announcements, and the company’s earnings call for signs of renewed pessimism. The momentum could dissipate once the company confirms cost‑control milestones, but a lag in execution may prolong the negative trend.
What Moves MOH Stock?
Molina Healthcare’s share price is most sensitive to the mix of Medicare Advantage versus Medicaid and the company’s ability to tighten cost controls. A shift in enrollment or a regulatory tweak can swing margins enough to move the stock, while the broader ACA exit strategy has been a recurring theme in recent coverage. The 41% year‑to‑date rally has largely been driven by margin expansion in Medicare Advantage, but recent target cuts hint at potential upside compression.
Medicare Advantage Mix
A tighter Medicare Advantage mix typically lifts gross margins, which historically translates into a 2–3% share rally on earnings days.
The segment is built on capitated contracts, giving Molina pricing power over drugs and allowing efficient utilization management.
In Q1 2026 Medicare Advantage revenue rose 3% and margin expanded 1.5 percentage points, helping the company beat EPS estimates by $0.41.
Medicaid Enrollment Trends
Medicaid enrollment drives volume; higher enrollment increases revenue but can compress margins if cost control lags.
Q2 2026 saw Medicaid revenue dip 1.5% while enrollment grew 2%, reflecting higher utilization costs that pushed EPS below estimates.
A 1% increase in Medicaid enrollment often leads to a modest 1% share decline if cost control measures are not in place.
ACA Marketplace Exit
The planned 2027 exit from the ACA marketplace has been priced into the stock, with recent target cuts reflecting potential revenue erosion.
The marketplace segment offered lower margins and higher churn; its removal is expected to improve the mix toward Medicare Advantage.
In Q4 2025, the marketplace contributed 4% of revenue but only 1% of EPS, prompting analysts to downgrade the segment’s outlook.
Cost Control Initiatives
Molina’s internal cost‑control programs target drug procurement and provider network efficiencies.
The 2025 cost‑control initiative reduced operating expenses by 3% YoY, helping to lift EPS to $6.08 in Q1 2025.
Effective cost cuts tend to generate a 1–2% uptick in share price as margins tighten, while failures can trigger sell‑offs.
Key insight: The single most important takeaway for investors is that Molina’s valuation is tightly coupled to its Medicare Advantage mix and the effectiveness of its cost‑control engine; any shift in enrollment or regulatory policy that erodes margins will quickly translate into share price swings.
Frequently Asked Questions About MOH
How does MOH’s cost structure compare to its peers?
MOH’s operating leverage is moderate, with a current P/E of 21.7 versus the peer average of 53. The company’s focus on Medicaid and Medicare allows it to achieve economies of scale, but it also faces higher regulatory costs. The margin trajectory has improved in recent quarters, reflecting tighter cost control. Compared to peers like AbbVie and Abbott Laboratories, MOH’s cost structure is more sensitive to reimbursement changes, underscoring the importance of monitoring payer mix dynamics.
Learn More
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).